ArticlePediatric blood & cancer2021
How we approach thrombosis risk in children with COVID-19 infection and MIS-C.
Article in Pediatric blood & cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 39 citations in OpenAlex.
- Multisystem inflammatory syndrome in children and Kawasaki disease.Frontiers in immunology · 2025Review
- Asymptomatic SARS-COV2 Infection or COVID-19 vaccination effect for severe multisystem inflammatory syndrome in a 6-year-old girl: case report and review of the literature.Italian journal of pediatrics · 2024Review
- COVID-19 and cardiac complications: Myocarditis and multisystem inflammatory syndrome in children.World journal of cardiology · 2024Review
- Treatment of multisystem inflammatory syndrome in children.World journal of pediatrics : WJP · 2024Review
- Management of Multisystem Inflammatory Syndrome in Children: Decision-Making Regarding a New Condition in the Absence of Clinical Trial Data.The Canadian journal of cardiology · 2023Review
- Multisystem inflammatory syndrome in children (MIS-C) and neonates (MIS-N) associated with COVID-19: optimizing definition and management.Pediatric research · 2023Review
- An extremely rare cause of flank pain: Answers.Pediatric nephrology (Berlin, Germany) · 2023Article
- Thrombotic Events in MIS-C Patients: A Single Case Report and Literature Review.Children (Basel, Switzerland) · 2023Article
- Current practices in pediatric hospital-acquired thromboembolism: Survey of the Children's Hospital Acquired Thrombosis (CHAT) Consortium.Research and practice in thrombosis and haemostasis · 2022Article
- Pulmonary embolism in pediatric and adolescent patients with COVID-19 infection during the SARS-CoV-2 delta wave.Pediatric blood & cancer · 2022Article
- Thromboprophylaxis for children hospitalized with COVID-19 and MIS-C.Research and practice in thrombosis and haemostasis · 2022Article
- Children with trisomy 21 are a group at risk for severe COVID-19: Case reports from a COVID-19 treatment unit in Addis Ababa, Ethiopia.Frontiers in pediatrics · 2022Article
- Intracardiac Thrombosis in the Three-Year-Old Boy with Normal Left Ventricle Systolic Function in MIS-C Associated with COVID-19.Mediterranean journal of hematology and infectious diseases · 2022Article
- Hematologic manifestations of coronavirus disease 2019 in children: Case-series report and a review.Frontiers in pediatrics · 2022Article
- Treatment of MIS-C in Children and Adolescents.Current pediatrics reports · 2022Review
- How we approach thrombosis risk in children with COVID-19 infection and MIS-C.Pediatric blood & cancer · 2021Article
- The Trilogy of SARS-CoV-2 in Pediatrics (Part 3): Thrombosis, Anticoagulant, and Antiplatelet Considerations.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Thrombosis within the microvasculature and medium to large vessels is a serious and common complication among critically ill individuals with coronavirus disease 2019 (COVID-19). While children are markedly less likely to develop severe disease than adults, they remain at risk for thrombosis during acute infection and with the post-acute inflammatory illness termed multisystem inflammatory syndrome in children. Significant knowledge deficits in understanding COVID-19-associated coagulopathy and thrombotic risk pose clinical challenges for pediatric providers who must incorporate expert opinion and personal experience to manage individual patients. We discuss clinical scenarios to provide framework for characterizing thrombosis risk and thromboprophylaxis in children with COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.